Tegaserod analytical method [Regulatives / Guidelines]

posted by Ayman Rabayah – Jordan, 2020-04-08 13:23 (1034 d 17:45 ago) – Posting: # 21318
Views: 1,079

Hello colleagues
I hope you are in good health and conditions, and wish the the COVID-19 crisis come to end in all countries.
kindly we are developing an analytical method for Tegaserod in human plasma, if you have an experience with this product (6 mg dose), is the metabolite M29 need to be included to be detected and measured, and if an LLOQ of 50 pg/ml will be enough?

looking to hear your advises
Thank you

Complete thread:

UA Flag
Activity
 Admin contact
22,481 posts in 4,710 threads, 1,603 registered users;
23 visitors (0 registered, 23 guests [including 9 identified bots]).
Forum time: 06:09 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5